دورية أكاديمية
Potential, Limitations and Risks of Cannabis-Derived Products in Cancer Treatment.
| العنوان: | Potential, Limitations and Risks of Cannabis-Derived Products in Cancer Treatment. |
|---|---|
| المؤلفون: | Woerdenbag HJ; Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands., Olinga P; Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands., Kok EA; Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands., Brugman DAP; Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands., van Ark UF; Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands., Ramcharan AS; Transvaal Apotheek, Kempstraat 113, 2572 GC Den Haag, The Netherlands., Lebbink PW; Transvaal Apotheek, Kempstraat 113, 2572 GC Den Haag, The Netherlands., Hoogwater FJH; Department of Surgery, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands., Knapen DG; Department of Medical Oncology, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands., de Groot DJA; Department of Medical Oncology, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands., Nijkamp MW; Department of Surgery, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands. |
| المصدر: | Cancers [Cancers (Basel)] 2023 Apr 01; Vol. 15 (7). Date of Electronic Publication: 2023 Apr 01. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Basel, Switzerland : MDPI |
| مستخلص: | The application of cannabis products in oncology receives interest, especially from patients. Despite the plethora of research data available, the added value in curative or palliative cancer care and the possible risks involved are insufficiently proven and therefore a matter of debate. We aim to give a recommendation on the position of cannabis products in clinical oncology by assessing recent literature. Various types of cannabis products, characteristics, quality and pharmacology are discussed. Standardisation is essential for reliable and reproducible quality. The oromucosal/sublingual route of administration is preferred over inhalation and drinking tea. Cannabinoids may inhibit efflux transporters and drug-metabolising enzymes, possibly inducing pharmacokinetic interactions with anticancer drugs being substrates for these proteins. This may enhance the cytostatic effect and/or drug-related adverse effects. Reversely, it may enable dose reduction. Similar interactions are likely with drugs used for symptom management treating pain, nausea, vomiting and anorexia. Cannabis products are usually well tolerated and may improve the quality of life of patients with cancer (although not unambiguously proven). The combination with immunotherapy seems undesirable because of the immunosuppressive action of cannabinoids. Further clinical research is warranted to scientifically support (refraining from) using cannabis products in patients with cancer. |
| References: | Oxid Med Cell Longev. 2022 May 25;2022:4619760. (PMID: 35669853) Anticancer Res. 2018 Oct;38(10):5831-5835. (PMID: 30275207) Am J Med. 2019 Nov;132(11):1266-1270. (PMID: 31152723) Oncologist. 2007 Mar;12(3):291-300. (PMID: 17405893) J Pain. 2015 Dec;16(12):1233-1242. (PMID: 26385201) J Pain Symptom Manage. 2016 Jun;51(6):1070-1090.e9. (PMID: 27112310) J Psychoactive Drugs. 2013 Jul-Aug;45(3):199-210. (PMID: 24175484) J Cannabis Res. 2022 Jul 11;4(1):37. (PMID: 35820952) J Cannabis Res. 2021 Aug 31;3(1):40. (PMID: 34465400) Oncologist. 2019 Apr;24(4):549-554. (PMID: 30670598) Medicines (Basel). 2018 Dec 23;6(1):. (PMID: 30583596) Neuropsychopharmacology. 2022 Nov 16;:. (PMID: 36380220) Cancer Treat Rev. 2019 Aug;78:17-30. (PMID: 31325788) F1000Res. 2019 Aug 8;8:1394. (PMID: 32117565) Drug Metab Dispos. 2011 Jul;39(7):1294-302. (PMID: 21511945) J Altern Complement Med. 2017 Nov;23(11):831-836. (PMID: 28799775) Bosn J Basic Med Sci. 2019 Feb 12;19(1):14-23. (PMID: 30172249) Emerg Infect Dis. 2020 Jun;26(6):1308-1310. (PMID: 32441624) iScience. 2020 Jul 24;23(7):101301. (PMID: 32629422) Eur J Intern Med. 2018 Mar;49:12-19. (PMID: 29307505) J Exp Clin Cancer Res. 2020 Oct 7;39(1):210. (PMID: 33028357) Eur J Pharmacol. 2008 Sep 4;591(1-3):128-31. (PMID: 18619955) Cancers (Basel). 2020 Aug 12;12(8):. (PMID: 32806706) PLoS One. 2023 Jan 30;18(1):e0267420. (PMID: 36716312) Front Pharmacol. 2019 Apr 05;10:339. (PMID: 31024307) Crit Care Nurs Clin North Am. 2015 Sep;27(3):315-39. (PMID: 26333754) Int J Mol Sci. 2020 Jan 23;21(3):. (PMID: 31979368) J Clin Psychopharmacol. 2019 Sep/Oct;39(5):462-471. (PMID: 31433338) J Control Release. 2018 Dec 10;291:184-195. (PMID: 30367922) J Cancer Res Clin Oncol. 2021 Sep;147(9):2507-2534. (PMID: 34259916) J Pain Symptom Manage. 2014 Jan;47(1):166-73. (PMID: 23742737) Schizophr Res. 2015 Mar;162(1-3):153-61. (PMID: 25667194) J Natl Cancer Inst. 1975 Sep;55(3):597-602. (PMID: 1159836) J Nat Prod. 2022 Jan 28;85(1):176-184. (PMID: 35007072) Drug Metab Dispos. 2011 Nov;39(11):2049-56. (PMID: 21821735) BMJ Open. 2021 Jul 28;11(7):e047717. (PMID: 34321302) Eur J Intern Med. 2018 Mar;49:2-6. (PMID: 29329891) Clin Ther. 2022 Dec;44(12):e39-e58. (PMID: 36411116) J Pain Symptom Manage. 2018 Feb;55(2):179-188.e1. (PMID: 28923526) Curr Protein Pept Sci. 2018;19(10):937-947. (PMID: 28969563) Int J Mol Sci. 2018 Mar 13;19(3):. (PMID: 29533978) Phytother Res. 2015 Mar;29(3):332-8. (PMID: 25504799) Front Pharmacol. 2022 May 25;13:888903. (PMID: 35694246) Br J Pharmacol. 2019 May;176(10):1384-1394. (PMID: 30019449) Front Pharmacol. 2021 Feb 02;11:599721. (PMID: 33708116) Br J Pharmacol. 2007 Nov;152(5):815-24. (PMID: 17906686) Phytother Res. 2021 Nov;35(11):6010-6029. (PMID: 34237796) Biol Psychiatry. 2016 Apr 1;79(7):516-25. (PMID: 26698193) Support Care Cancer. 2021 Dec;29(12):7471-7478. (PMID: 34085149) J Cannabis Res. 2022 Jun 6;4(1):28. (PMID: 35658956) Int J Mol Sci. 2021 Sep 18;22(18):. (PMID: 34576262) Molecules. 2021 Jun 24;26(13):. (PMID: 34202812) CNS Drugs. 2018 Nov;32(11):1053-1067. (PMID: 30374683) Cancers (Basel). 2020 Aug 28;12(9):. (PMID: 32872248) Br J Cancer. 2021 Apr;124(8):1379-1387. (PMID: 33623076) Front Pharmacol. 2019 Sep 27;10:1124. (PMID: 31611800) Clin Pharmacokinet. 2003;42(4):327-60. (PMID: 12648025) Ann Oncol. 2020 Nov;31(11):1553-1560. (PMID: 32801017) Mol Neurobiol. 2007 Aug;36(1):60-7. (PMID: 17952650) Front Pharmacol. 2018 Nov 26;9:1365. (PMID: 30534073) Expert Opin Investig Drugs. 2019 Mar;28(3):285-296. (PMID: 30572744) Front Oncol. 2021 May 21;11:649555. (PMID: 34094937) Expert Opin Pharmacother. 2013 Apr;14(6):757-66. (PMID: 23496347) Planta Med. 2023 Feb;89(2):119-133. (PMID: 35304735) Phytother Res. 2022 Jan;36(1):5-21. (PMID: 34841610) Mayo Clin Proc. 2019 Sep;94(9):1840-1851. (PMID: 31447137) Drugs. 2018 Nov;78(16):1665-1703. (PMID: 30374797) Perm J. 2020 Dec;25:1-3. (PMID: 33635755) Evid Based Complement Alternat Med. 2013;2013:510392. (PMID: 23956774) Toxics. 2020 Jun 03;8(2):. (PMID: 32503116) Biochem Pharmacol. 2006 Apr 14;71(8):1146-54. (PMID: 16458258) Planta Med. 2022 Jun 23;:. (PMID: 35338476) Cell Death Dis. 2011 Apr 28;2:e152. (PMID: 21525939) J Cancer Res Clin Oncol. 2023 May;149(5):1863-1872. (PMID: 35779108) Cannabis Cannabinoid Res. 2022 Dec 28;:. (PMID: 36579921) Addiction. 2023 Feb 7;:. (PMID: 36750134) Br J Clin Pharmacol. 2018 Nov;84(11):2477-2482. (PMID: 30001569) PeerJ. 2013 Sep 12;1:e153. (PMID: 24058883) Eur J Intern Med. 2018 Mar;49:37-43. (PMID: 29482741) Health Econ. 2021 Sep;30(10):2409-2436. (PMID: 34258798) Oncol Lett. 2016 Nov;12(5):4231-4237. (PMID: 27895797) Ther Adv Med Oncol. 2019 Aug 01;11:1758835919866362. (PMID: 31413731) Life Sci. 2011 Apr 11;88(15-16):730-6. (PMID: 21356216) Epilepsia. 2015 Aug;56(8):1246-51. (PMID: 26114620) Mol Cancer Ther. 2011 Jan;10(1):90-103. (PMID: 21220494) J Am Psychiatr Nurses Assoc. 2020 Sep/Oct;26(5):447-457. (PMID: 32508204) J Cachexia Sarcopenia Muscle. 2022 Feb;13(1):23-41. (PMID: 34881518) Neurourol Urodyn. 2020 Jan;39(1):158-169. (PMID: 31729056) Mol Neurobiol. 2007 Aug;36(1):36-44. (PMID: 17952648) Integr Cancer Ther. 2022 Jan-Dec;21:15347354221081772. (PMID: 35225051) Autoimmun Rev. 2016 Jun;15(6):513-28. (PMID: 26876387) JAMA Netw Open. 2023 Feb 1;6(2):e2254752. (PMID: 36780161) PLoS One. 2021 Aug 5;16(8):e0255591. (PMID: 34352013) Clin Pharmacol Ther. 2011 Dec;90(6):844-51. (PMID: 22048225) Front Pain Res (Lausanne). 2022 May 20;3:861037. (PMID: 35669038) Adv Pharmacol. 2017;80:397-436. (PMID: 28826542) Drug Metab Dispos. 2021 Dec;49(12):1081-1089. (PMID: 34493601) Adv Pharmacol. 2018;83:65-91. (PMID: 29801584) Int J Mol Sci. 2021 Apr 01;22(7):. (PMID: 33916164) Biochem Pharmacol. 2018 Nov;157:285-293. (PMID: 29940172) Int J Mol Sci. 2019 Nov 25;20(23):. (PMID: 31775230) Cannabis Cannabinoid Res. 2021 Dec;6(6):474-487. (PMID: 34664988) Ann Palliat Med. 2017 Dec;6(Suppl 2):S209-S214. (PMID: 29156899) Front Mol Neurosci. 2019 Jan 15;11:487. (PMID: 30697147) Front Oncol. 2019 Jan 18;8:643. (PMID: 30713832) Br J Cancer. 2022 Jul;127(1):1-13. (PMID: 35277658) Neth J Med. 2001 Oct;59(4):196-207. (PMID: 11578795) Cancers (Basel). 2021 Jan 05;13(1):. (PMID: 33466435) Int J Drug Policy. 2021 Aug;94:103202. (PMID: 33765514) Front Med (Lausanne). 2022 Feb 09;9:827849. (PMID: 35223923) Neurogastroenterol Motil. 2017 Mar;29(3):. (PMID: 27686064) J Nat Prod. 2020 Apr 24;83(4):1334-1351. (PMID: 32281793) Front Pharmacol. 2019 May 31;10:621. (PMID: 31214034) Cancers (Basel). 2021 Aug 15;13(16):. (PMID: 34439262) Fundam Clin Pharmacol. 2018 Oct;32(5):462-484. (PMID: 29660159) J Clin Oncol. 2023 Mar 1;41(7):1444-1452. (PMID: 36409969) Curr Neuropharmacol. 2020;18(2):87-96. (PMID: 31481004) Int J Mol Sci. 2020 Oct 17;21(20):. (PMID: 33080916) Mol Cancer Ther. 2014 Dec;13(12):2955-67. (PMID: 25398831) CPT Pharmacometrics Syst Pharmacol. 2017 Sep;6(9):576-588. (PMID: 28653357) Drug Metab Pharmacokinet. 2012;27(3):294-300. (PMID: 22166891) Support Care Cancer. 2018 Sep;26(9):3029-3038. (PMID: 29550881) Drug Metab Dispos. 2022 Apr;50(4):351-360. (PMID: 35115300) Pharmaceuticals (Basel). 2021 Jan 29;14(2):. (PMID: 33572935) Curr Pharm Des. 2012;18(32):5131-40. (PMID: 22716160) J Pain Symptom Manage. 2010 Feb;39(2):167-79. (PMID: 19896326) Pharmaceutics. 2021 Apr 23;13(5):. (PMID: 33922481) Br J Clin Pharmacol. 2015 Feb;79(2):241-53. (PMID: 25125025) Front Plant Sci. 2016 Feb 04;7:19. (PMID: 26870049) BMJ. 2021 Sep 8;374:n1034. (PMID: 34497047) Support Care Cancer. 2022 Feb;30(2):1181-1190. (PMID: 34453567) Drugs Aging. 2022 Feb;39(2):153-163. (PMID: 34940961) J Mol Endocrinol. 2010 Feb;44(2):75-85. (PMID: 19620237) |
| فهرسة مساهمة: | Keywords: cancer treatment; cannabidiol (CBD); cannabinoids; cannabis products; delta-9-tetrahydrocannabinol (THC); drug interactions; oncology; quality of life; symptom management |
| تواريخ الأحداث: | Date Created: 20230413 Latest Revision: 20230415 |
| رمز التحديث: | 20230415 |
| مُعرف محوري في PubMed: | PMC10093248 |
| DOI: | 10.3390/cancers15072119 |
| PMID: | 37046779 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2072-6694 |
|---|---|
| DOI: | 10.3390/cancers15072119 |